CTPharma Revenue and Competitors
Estimated Revenue & Valuation
- CTPharma's estimated annual revenue is currently $3.5M per year.
- CTPharma's estimated revenue per employee is $116,667
Employee Data
- CTPharma has 30 Employees.
- CTPharma grew their employee count by 0% last year.
CTPharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Cultivation Director | Reveal Email/Phone |
2 | Cultivation Manager | Reveal Email/Phone |
3 | Quality Assurance Manager | Reveal Email/Phone |
4 | Product Photographer | Reveal Email/Phone |
5 | Operations Supervisor | Reveal Email/Phone |
6 | Grower | Reveal Email/Phone |
7 | Executive Assistant | Reveal Email/Phone |
CTPharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 5 | 25% | N/A | N/A |
#2 | N/A | 8 | -11% | N/A | N/A |
#3 | $3.5M | 29 | 12% | N/A | N/A |
#4 | N/A | 23 | 109% | N/A | N/A |
#5 | N/A | 30 | 7% | $12.9M | N/A |
#6 | $1.7M | 186 | -1% | N/A | N/A |
#7 | $15M | 12 | 0% | N/A | N/A |
#8 | $3.5M | 30 | 0% | N/A | N/A |
What Is CTPharma?
Since 2014, we have provided top-quality marijuana products to improve patients’ lives. We are licensed to grow and process medicinal marijuana products for adult and pediatric patients. We invest in best practices to ensure that patients have access to effective options. We constantly research new formulations of cannabinoid-based treatments to create pharmaceutically elegant products that improve people’s well-being and help them live their best lives. By investing in people, practices, and infrastructure, we are shaping a new industry. Our goal is to be a trusted brand that our patients can rely on.
keywords:N/AN/A
Total Funding
30
Number of Employees
$3.5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.4M | 30 | 3% | N/A |
#2 | $6.7M | 31 | -14% | N/A |
#3 | $6.9M | 32 | -9% | N/A |
#4 | $4.6M | 33 | 3% | N/A |
#5 | $3.8M | 33 | 6% | N/A |